Page 4 - System Preparedness News Today : Breaking News, Live Updates & Top Stories | Vimarsana

THE DAVOS ALZHEIMER’S COLLABORATIVE LAUNCHES INNOVATIVE EARLY DETECTION EFFORT Seven Flagship Pilot Sites Aim to Measurably Increase Timely, Accurate Diagnosis of Alzheimer’s GlobeNewswire May 03, 2022 New York, NY, May 03, 2022 (GLOBE NEWSWIRE) -- Unique global collaboration to prepare health systems for a future with new Alzheimer’s treatmentsPioneering use of blood-based biomarkers with...

Seven Flagship Pilot Sites Aim to Measurably Increase Timely, Accurate Diagnosis of Alzheimer’s...

The first international Conference on Public Health in Africa (CPHIA2021), hosted by the African Union (AU) and Africa Centres for Disease (...)

Wednesday, March 10 Lecture Time: 12:45 - 13:00 Live Discussion: 17:00 - 17:30 Cerebrospinal Fluid Biomarker Concordance with Amyloid PET in EMERGE/ENGAGE, Phase 3 Studies of Aducanumab in Patients with Early Alzheimer's Disease Session: Aβ Targeting Therapies in AD 2 Saturday, March 13 Lecture Time: 12:45 - 13:00 Live Discussion: 17:30 - 18:00 Evaluation of Aducanumab Efficacy in Early Alzheimer's Disease. Session: Aβ Targeting Therapies in AD 2 Saturday, March 13 Lecture Time: 13:00 - 13:15 Live Discussion: 17:30 - 18:00  Evaluation of Aducanumab Safety in Early Alzheimer's Diseas...

Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data - Oral presentations and posters highlighting Eisai's investigational novel therapies and immunoassay system being studied for Alzheimer's disease and its clinical symptoms - Preliminary analyses evaluating brain amyloid beta reduction with lecanemab to be featured in oral presentation - Virtual symposium: The Science Behind the Aβ Pathway in Alzheimer's Disease News provided by Share this article Share this article WOODCLIFF LAKE, N.J., March 5, 2021 /PRNewswire/ -- Eisa...